RecruitingPhase 2NCT04659811

Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma

Studying Meningioma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Nancy Ann Oberheim Bush, MD
Principal Investigator
Nancy Oberheim Bush, MD, PhD, MD, PHD
University of California, San Francisco
Intervention
Pembrolizumab(drug)
Enrollment
37 enrolled
Eligibility
18 years · All sexes
Timeline
20212030

Study locations (1)

Collaborators

Merck Sharp & Dohme LLC

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04659811 on ClinicalTrials.gov

Other trials for Meningioma

Additional recruiting or active studies for the same condition.

See all trials for Meningioma

← Back to all trials